Latest Period
n/a
Security Snapshot
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 Institutional Ownership
CUSIP: 40637HAF6
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
Principal
Price (% of par)
128.72%
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 1.000% 8/1
- SEC-reported market price (% of par)
- 128.72%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 40637HAF6 - HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 is tracked under CUSIP 40637HAF6.
- Latest finished 13F holder period is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 2 to 1 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $44,254,737 to $14,940,066.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
40637HAF6
Latest holder period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 40637HAF6:
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
n/a
Rows shown
1-6 of 6
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | $11,607,000 | $14,940,066 | 128.72% | 1 | |
| 2025 Q4 | $33,330,000 | $44,254,737 | +$6,865,777 | 132.73% | 2 |
| 2024 Q3 | $13,700,000 | $16,312,058 | -$1,190,661 | 119.07% | 1 |
| 2024 Q2 | $49,955,000 | $55,565,279 | +$31,877,723 | 111.28% | 2 |
| 2024 Q1 | $21,275,000 | $20,724,289 | +$803,256 | 97.33% | 2 |
| 2023 Q4 | $20,450,000 | $19,055,621 | 93.01% | 2 |